Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi’s sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial

[1]  C. Supuran,et al.  Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. , 2007, Current medicinal chemistry.

[2]  N. Hariparsad,et al.  Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions , 2007, Drug Metabolism and Disposition.

[3]  S. Montaner.  Akt/TSC/mTOR Activation by the KSHV G Protein-Coupled Receptor: Emerging Insights into the Molecular Oncogenesis and Treatment of Kaposi’s Sarcoma , 2007, Cell cycle.

[4]  Zan Huang,et al.  Intracellular Tat of Human Immunodeficiency Virus Type 1 Activates Lytic Cycle Replication of Kaposi's Sarcoma-Associated Herpesvirus: Role of JAK/STAT Signaling , 2006, Journal of Virology.

[5]  L. Pantanowitz,et al.  The growing problem of non-AIDS-defining malignancies in HIV , 2006, Current opinion in oncology.

[6]  A. Sparreboom,et al.  Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. , 2005, Anticancer research.

[7]  J. Schellens,et al.  No pharmacokinetic drug–drug interaction between nevirapine and paclitaxel , 2005, Anti-cancer drugs.

[8]  S. Steinberg,et al.  Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced Cancer , 2005, Clinical Cancer Research.

[9]  M. Boffito,et al.  Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors. , 2004, AIDS reviews.

[10]  D. Podzamczer,et al.  Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma , 2004, AIDS.

[11]  G. Tosato,et al.  HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. , 2004, Blood.

[12]  J. Verweij,et al.  Paclitaxel pharmacokinetics, threshold models, and dosing strategies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Brizzi,et al.  HIV-1-Tat Protein Activates Phosphatidylinositol 3-Kinase/ AKT-dependent Survival Pathways in Kaposi's Sarcoma Cells* , 2002, The Journal of Biological Chemistry.

[14]  A. Tulpule,et al.  Multicenter trial of low‐dose paclitaxel in patients with advanced AIDS‐related Kaposi sarcoma , 2002, Cancer.

[15]  D. Scadden,et al.  Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Grochow,et al.  Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Zucchetti,et al.  The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma , 2000, Cancer Chemotherapy and Pharmacology.

[18]  J. Margolick,et al.  Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. , 1999, Journal of acquired immune deficiency syndromes.

[19]  A. Tulpule,et al.  Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Kuper,et al.  Drug Interactions of HIV Protease Inhibitors , 1999, Drug safety.

[21]  J. Beijnen,et al.  Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma – drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study , 1999, Cancer Chemotherapy and Pharmacology.

[22]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[23]  W. Wilson,et al.  Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Verweij,et al.  Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[25]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Masood,et al.  Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Giaccone,et al.  Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Rosenberg,et al.  Kaposi's sarcoma and non‐Hodgkin's lymphoma following the diagnosis of AIDS , 1996 .

[29]  Andrew Carr,et al.  HIV protease inhibitors , 1996, AIDS.

[30]  P. Rosenberg,et al.  Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group. , 1996, International journal of cancer.

[31]  D. Ho,et al.  Time to hit HIV, early and hard. , 1995, The New England journal of medicine.

[32]  W. Wilson,et al.  Treatment of HIV-associated Kaposi's sarcoma with paclitaxel , 1995, The Lancet.

[33]  P. Moore,et al.  Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. , 1995, The New England journal of medicine.

[34]  G. Bonadonna,et al.  Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  E. Cesarman,et al.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. , 1994, Science.

[36]  M. Relling,et al.  Clinical Pharmacokinetics of Paclitaxel , 1994, Clinical pharmacokinetics.

[37]  F. Guengerich,et al.  Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. , 1994, Cancer research.

[38]  J J Shuster,et al.  Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Krown,et al.  Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Krown,et al.  Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: A Proposal for Uniform Evaluation, Response, and Staging Criteria , 1989 .